Skip to content
Homepage
Author:
Tvardi Therapeutics
Posted Date:
July 7, 2026
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
Tvardi Therapeutics
July 7, 2026
Tvardi Therapeutics to Participate in Upcoming Investor Events
Tvardi Therapeutics
May 29, 2026
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
Tvardi Therapeutics
May 27, 2026
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
Tvardi Therapeutics
May 23, 2026
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
Tvardi Therapeutics
May 22, 2026
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
Tvardi Therapeutics
February 12, 2026
